Coin News

How to market to Bitcoin owners without Bitcoin's volatility.

The post Solve This Videogame’s “Mind-Blowing” Test, Get a Bitcoin appeared first on CCN

Beat the game, win a Bitcoin. Simple, right? That’s the premise of MonteCrypto: The Bitcoin Enigma, a PC game scheduled for release next week. The mysterious game, the latest in a long tradition of public treasure hunts, offers players the opportunity to achieve a lucrative payday — if they can solve the game’s two dozen

The post Solve This Videogame’s “Mind-Blowing” Test, Get a Bitcoin appeared first on CCN

The post Bitcoin Mining Facility Interferes With T-Mobile’s LTE Network Verifying Payments appeared first on CCN

US Federal Communications Commission (FCC) revealed in an official “notification of harmful interference” document that a bitcoin mining facility based in Brooklyn, New York interfered with T-Mobile’s LTE network by sending harmful radio emissions to the telecom’s 700 MHz band. Antminer Interferes With LTE Network The FCC noted in an document published on February 15

The post Bitcoin Mining Facility Interferes With T-Mobile’s LTE Network Verifying Payments appeared first on CCN

• Private-equity giant Blackstone Group has promoted Jonathan Gray to replace Tony James as COO.
• Gray, 48, has run the firm's global real estate group since 2005.
• Gray joined the firm out of college in 1992 and has built a billion-dollar fortune in his time there.

Alternative-asset management giant Blackstone Group has tapped 48-year-old billionaire Jonathan Gray as its next chief operating officer, the company announced Tuesday. 

Gray, who has run the firm's massive global real estate group since 2005, replaces long-time president and COO Tony James, who will slide into the role of executive vice chairman. 

Gray joined the firm fresh out of college in 1992 and has long been viewed as a potential successor to founder and CEO Steve Schwarzman, whom he will report to. 

"I've learned over the last 26 years that Jon Gray has great judgment, enormous energy and unique personal charisma, which has enabled him to garner enormous respect within the global financial community," Schwarzman said in the statement. "His strong values and passion for excellence are the embodiment of Blackstone’s core principles. The appointment of Jon as President and COO lays the foundation for the next generation of senior management and positions the firm well for future leadership.”

Like Schwarzman, who is worth $12.8 billion according to Forbes, Gray has built a massive fortune in his years running real estate for the company. Forbes estimates his net worth at $2.5 billion. 

"I have spent my entire career at Blackstone and could not be more proud to be part of this firm," Gray said in the statement.  "Despite our tremendous success to date, I am quite excited about the opportunity to continue to innovate for both our investors and shareholders."

Join the conversation about this story »

NOW WATCH: Ken Rogoff on the next financial crisis and the future of bitcoin

• It's been a while since we've had good news in search for new Alzheimer's drugs.
• On Tuesday, Merck said it was discontinuing one of its remaining trials that was looking at using the treatment in patients very early on in the disease. 
• A number of trials are still ongoing, testing out new hypotheses to see if there's a way to tackle Alzheimer's better than we can today. 

Things are pretty bleak in the search to find new Alzheimer's treatments. 

In February alone, the CEO of Axovant stepped down after 10 months on the job and a failed Alzheimer's trial. And Merck said it was cancelling a trial looking at Alzheimer's treatments in early stage patients, concluding that "it was unlikely that positive benefit/risk could be established if the trial continued."

A year ago, in February 2017, Merck stopped an earlier late-stage trial of verubecestat in patients with mild to moderate Alzheimer's, after a committee found that there was "virtually no chance of finding a positive clinical effect." The hope was to have the drug — a BACE inhibitor — stop the disease from progressing. 

"In a way, the writing was on the wall," Bernstein analyst Tim Anderson said in a note Tuesday, after the latest cancellation. Anderson pointed to the fact that Merck's head of neuroscience had left the company in early 2018 as a sign that things likely weren't going well. 

Alzheimer's affects more than 5 million Americans, a number that's expected to balloon to 13.8 million by 2050 . There are only four drugs that have been approved to treat the symptoms of the disease, and the most recent drug approval happened in 2003.

What's ahead

According to an industry report, there are more than a dozen experimental treatments that are still in phase 3, the latest stage of clinical trials before companies present their data to the FDA. Here are some of the ones to look out for in the next year or two.

• VTV Therapeutics, a small company in North Carolina, has an Alzheimer's drug in late-stage trials called azeliragon that inhibits the RAGE receptor, ideally helping people with mild Alzheimer's delay cognitive decline. Its phase 3 trial is expected to wrap up in early 2018. The company got encouraging phase 2 results on the drug, which has been in the works for about 17 years. Even so, there's no guarantee it will succeed. "We are doing a sound and rigorous experiment," Dr. Larry Altstiel, VTV's chief medical officer told Business Insider.
• Biogen's aducanumab, is going after the " amyloid hypothesis," or the idea that targeting beta amyloid deposits in the brain to clear them out is the way to go about treating the disease. It's expected to have results in 2019 or early 2020.
• Lanabecestat, AstraZeneca's BACE inhibitor, is going be reading out in 2019. Like Biogen, it's going after the amyloid hypothesis.
• Eli Lily's solanezumab failed a phase 3 trial in patients with mild dementia in November 2016, but has plans to keep trying the drug in pre-clinical stages of the disease to see if it works preventatively. Solanezumab is going after the amyloid hypothesis as well. While three trials have been disconnected, the fourth in this preventive setting is expected to have results in 2022.
• Genentech has two Alzheimer's drugs in late-stage development, despite hitting setbacks. In February, Genentech and its partner AC Immune launched a phase 3 trial for crenezumab, another drug that's targeting amyloid deposits in the brain. It's expected to have data in 2020. The other is gantenerumab, a drug also targeting amyloid that failed earlier trials. The hope is that by increasing the dose, it might work. Genentech started a new phase 3 trial for gantenerumab in 2017.

SEE ALSO: The CEO of a biotech founded by a 32-year old is stepping down after 10 months — and the stock is crashing

DON'T MISS: The entire healthcare business is being redrawn — and it's anybody's guess what's going to happen next

Join the conversation about this story »

NOW WATCH: Ken Rogoff on the next financial crisis and the future of bitcoin

• The 24-year-old founder of Ethereum has warned that cryptocurrencies could drop at any time.
• He added that nobody should invest more than they can afford to lose.
• Ethereum is the second most valuable cryptocurrency.

The founder of Ethereum, the second most valuable cryptocurrency in the world, has warned that cryptocurrencies "could drop to near zero at any time."

To those interested in investing, 24-year-old Russian-Canadian programmer and writer Vitalik Buterin also suggested: "Don't put in more money than you can afford to lose."

The warning came via a tweet on Buterin's account on Saturday.

The full message read: "Reminder: cryptocurrencies are still a new and hyper-volatile asset class, and could drop to near-zero at any time. Don't put in more money than you can afford to lose. If you're trying to figure out where to store your life savings, traditional assets are still your safest bet."

The response to Twitter warning was divided.

Some users suggested Buterin was creating "unnecessary panic."

Some outright disagreed with him...

...And some simply joked that the advice was coming too late.

SEE ALSO: ETHEREUM FOUNDER: 'I won't stop or slow working on crypto just because price memes and stupid jokes exist'

SEE ALSO: Bitcoin is jumping — but the entire crypto market is still 'trading sideways'

Join the conversation about this story »

NOW WATCH: The CEO of $445 billion fund giant Principal Global Investors says everyone has the economy all wrong

The post The World Needs a New Kind of Currency, Bitcoin: Investor Tim Draper appeared first on CCN

Tim Draper, the founder of venture capital firm Draper Fisher Jurvetson, says the world needs a new kind of currency. Speaking from Stanford, California, Draper, an early investor in Bitcoin and a victim of the infamous 2014 Mt. Gox hack, spoke to Bloomberg TV of his confidence in cryptocurrencies. Draper lost around 40,000 Bitcoins in … Continued

The post The World Needs a New Kind of Currency, Bitcoin: Investor Tim Draper appeared first on CCN

The post Cryptocurrency Market Recovers to $500 Billion as Bitcoin, Ethereum Record Gains appeared first on CCN

For the first time in February, the cryptocurrency market has recovered to $500 billion, as most major cryptocurrencies including bitcoin and Ethereum recorded large gains in the past two days. Within the past 24 hours, bitcoin recorded a price increase 9 percent, rising from $10,030 to $10,850. Premiums in the South Korean cryptocurrency market have

The post Cryptocurrency Market Recovers to $500 Billion as Bitcoin, Ethereum Record Gains appeared first on CCN

The post Popular Online Casino Site Adds Bitcoin as a Payment Option appeared first on CCN

This is a paid-for submitted press release. CCN does not endorse, nor is responsible for any material included below and isn’t responsible for any damages or losses connected with any products or services mentioned in the press release. CCN urges readers to conduct their own research with due diligence into the company, product or service mentioned

The post Popular Online Casino Site Adds Bitcoin as a Payment Option appeared first on CCN

This article originally appeared on Bitcoin Magazine.